Emerging at the UK, retatrutide, a novel molecule, is generating considerable excitement within the scientific community regarding its promise for body regulation. This dual GIP and GLP-1 receptor agonist looks to offer a substantial advantage over existing therapies, showing promising results in early clinical studies . Researchers believe its dis